Next-gen pso­ri­a­sis drug ri­val­ry be­tween Bris­tol My­ers and Nim­bus spills in­to a le­gal bat­tle

When Bris­tol My­ers Squibb de­cid­ed to ac­quire Cel­gene for $80 bil­lion in 2019, the two were forced to di­vest pso­ri­a­sis drug Ote­zla to Am­gen in or­der to avoid a mo­nop­oly in that mar­ket.

But it’s the ri­val­ry over the next gen­er­a­tion of pso­ri­a­sis drugs be­tween Bris­tol My­ers and Nim­bus Ther­a­peu­tics that could turn in­to an an­ti-com­pet­i­tive mo­nop­oly, Nim­bus al­leges in a new law­suit filed late last week.

Both Bris­tol My­ers and Nim­bus are the fur­thest bio­phar­ma com­pa­nies along with de­vel­op­ing what are known as al­losteric TYK2 in­hibitors, which have the po­ten­tial to treat pso­ri­a­sis and oth­er au­toim­mune dis­eases with a sim­i­lar or bet­ter safe­ty pro­file, and marked­ly im­proved ef­fi­ca­cy, when com­pared to the lead­ing cur­rent treat­ment, which is Ote­zla.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER